The cranial sutures are the primary sites of bone formation during skull growth. Morphogenesis and phenotypic maintenance of the cranial sutures are regulated by tissue interactions, especially those with the underlying dura mater. Removal of the dura mater in fetuses causes abnormal suture development and premature suture obliteration. The dura mater interacts with overlying tissues of the cranial vault by providing: (1) intercellular signals, (2) mechanical signals and (3) cells, which undergo transformation and migrate to the suture. The intercellular signaling governing suture development employs the fibroblast growth factors (FGFs). In rats during formation of the sutures in the fetus, FGF-1 is localized mainly in the dura mater, while other FGFs are expressed in the overlying tissues. By birth, FGF-2 largely replaces FGF-1 in the dura mater. FGFs present in the calvaria bind either the IIIb or IIIc mRNA splice variants of the FGF receptors (FGFRs) 1, 2, or 3. Monoclonal antibodies to the b variant of FGFR2 were used to determine the distribution of FGFR2IIIb during suture development and its extracellular localization. FGFR2IIIb is present in association with mature osteoblasts and osteogenic precursor cells of the suture in the fetus. Ectodomains of FGFR2IIIb, the products of proteolytic cleavage of the receptors, were present throughout the extracellular matrix of sutures resisting obliteration (coronal and sagittal), but absent from the core of sutures undergoing normal fusion (posterior intrafrontal). This observation is consistent with a possible mechanism, in which truncated receptors bind FGFs, thus regulating free FGF available to nearby cells. Mechanical signaling in the calvaria results from tensional forces in the dura mater generated during rapid expansion of the neurocranium. Posterior intrafrontal sutures of rats, which fuse between days 16 and 24, were subjected to cyclical tensional forces in vitro. Significant delay in the timing of suture fusion and increases in the expression domains of FGFR1 and 2 were observed, demonstrating the sensitivity of suture patency to mechanical signals and a possible role of the FGF system in mediating such stimuli. Finally, cells of the dura mater beneath the intrafrontal and sagittal sutures were observed to undergo a morphological transformation to a dendritic morphology and migrate into the suture mesenchyme between days 10 and 16 of development. This process may participate in suture and bone morphogenesis and influence the patency of the sutures along the anterior-posterior axis.

1.
Arman, E., R. Haffner-Krausz, Y. Chen, J.K. Heath, P. Lonai (1998) Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc Natl Acad Sci USA 95: 5082–5087.
2.
Bradley, J.P., J.P. Levine, J.G. McCarthy, M.T. Longaker (1997) Studies in cranial suture biology: Regional dura mater determines in vitro cranial suture fusion. Plast Reconstr Surg 100: 1091–1099.
3.
Carlton, M.B., W.H. Colledge, M.J. Evans (1998) Crouzon-like craniofacial dysmorphology in the mouse is caused by an insertional mutation at the Fgf3/Fgf4 locus. Dev Dyn 212: 242–249.
4.
Celli, G., W.J. LaRochelle, S. Mackem, R. Sharp, G. Merlino (1998) Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 17: 1642–1655.
5.
Chai, Y., X. Jiang, Y. Ito, P. Bringas, Jr, J. Han, D.H. Rowitch, P. Soriano, A.P. McMahon, H.M. Sucov (2000) Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development 127: 1671–1679.
6.
Couly, G.F., P.M. Coltey, N.M. Le Douarin (1993) The triple origin of skull in higher vertebrates: A study in quail-chick chimeras. Development 117: 409–429.
7.
Deng, C., A. Wynshaw-Boris, F. Zhou, A. Kuo, P. Leder (1996) Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84: 911–921.
8.
Deng, C.X., A. Wynshaw-Boris, M. Shen, C. Daugherty, D. Ornitz, P. Leder (1994) Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 8: 3045–3057.
9.
Freyman, T.M., I.V. Yannas, R. Yokoo, L.J. Gibson (2001) Fibroblast contraction of a collagen-GAG matrix. Biomaterials 22: 2883–2891.
10.
Greenwald, J.A., B.J. Mehrara, J.A. Spector, S.M. Warren, P.J. Fagenholz, L.E. Smith, P.J. Bouletreau, F.E. Crisera, H. Ueno, M.T. Longaker (2001) In vivo modulation of FGF biological activity alters cranial suture fate. Am J Pathol 158: 441–452.
11.
Hajihosseini, M.K., J.K. Heath (2002) Expression patterns of fibroblast growth factors-18 and -20 in mouse embryos is suggestive of novel roles in calvarial and limb development. Mech of Dev 113: 79–83.
12.
Ignelzi, M.A., W. Wang, A.T. Young (2003) Fibroblast growth factors lead to increased msx2 expression and fusion in calvarial sutures. J Bone Miner Res 18: 751–759.
13.
Jiang, X., S. Iseki, R.E. Maxson, H. Sucov, G.M. Morriss-Kay (2002) Tissue origins and interactions in the mammalian skull vault. Dev Biol 241: 106–116.
14.
Kim, H.J., D.P. Rice, P.J. Kettunen, I. Thesleff (1998) FGF-, BMP- and Shh-mediated signalling pathways in the regulation of cranial suture morphogenesis and calvarial bone development. Development 125: 1241–1251.
15.
Liu, Y.H., R. Kundu, L. Wu, W. Luo, M.A. Ignelzi, Jr., M.L. Snead, R.E. Maxson (1995) Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. Proc Natl Acad Sci USA 92: 6137–6141.
16.
Mehrara, B.J., J.A. Spector, J.A. Greenwald, H. Ueno, M.T. Longaker (2002) Adenovirus-mediated transmission of a dominant negative transforming growth factor-beta receptor inhibits in vitro mouse cranial suture fusion. Plast Reconstr Surg 110(2): 506–514.
17.
Morriss-Kay, G.M. (2001) Derivation of the mammalian skull vault. J Anat 199: 143–151.
18.
Moss, M.L. (1960) Inhibition and stimulation of sutural fusion in the rat calvaria. Anat Rec 136: 457–467.
19.
Noden, D.M. (1986) Origins and patterning of craniofacial mesenchymal tissues. J Craniofac Genet Dev Biol 2(suppl): 15–31.
20.
Ogle, R.C. (2000) Craniofacial skeletal morphogenesis in vitro. Methods Mol Biol 136: 55–59.
21.
Ogle, R.C. (2002) Development and growth of the neurocranium; in Lin, K.Y., R.C. Ogle, J.A. Jane (eds): Craniofacial Surgery: Science and Surgical Technique. Philadelphia, Saunders, pp 164–174.
22.
Ogle, R.A., S.S. Tholpady, R.C. Ogle (2003) Distribution and shedding of fgf receptors during cranial development. Submitted.
23.
Ohbayashi, N., M. Shibayama, Y. Kurotaki, M. Imanishi, T. Fujimori, N. Itoh, S. Takada (2002) FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev 16: 870–879.
24.
Opperman, L.A., T.M. Sweeney, J. Redmon, J.A. Persing, R.C. Ogle (1993) Tissue interactions with underlying dura mater inhibit osseous obliteration of developing cranial sutures. Dev Dyn 198: 312–322.
25.
Opperman, L.A., R.W. Passarelli, E.P. Morgan, M. Reintjes, R.C. Ogle (1995) Cranial sutures require tissue interactions with dura mater to resist osseous obliteration in vitro. J Bone Miner Res 10: 1978–1987.
26.
Opperman, L.A., R.W. Passarelli, A.A. Nolen, K.Y. Lin, T.G. Gampper, R.C. Ogle (1996) Dura mater secretes soluble, heparin-binding factors required for cranial suture morphogenesis. In Vitro Cell and Dev Biol 32: 627–632.
27.
Opperman, L.A., A. Chhabra, R.W. Cho, R.C. Ogle (1999) Cranial suture obliteration is induced by removal of transforming growth factor (TGF)-beta 3 activity and prevented by removal of TGF-beta 2 activity from fetal rat calvaria in vitro. J Craniofac Genet Dev Biol 19: 164–173.
28.
Opperman, L.A., V. Galanis, A.R. Williams, K. Adab (2002) Transforming growth factor-beta 3 (Tgf-beta3) in a collagen gel delays fusion of the rat posterior interfrontal suture in vivo. Anat Rec 267: 120–130.
29.
Pandit, S.G., P. Govindraj, J. Sasse, P.J. Neame, J.R. Hassell (2002) The fibroblast growth factor receptor, FGFR3, forms gradients of intact and degraded protein across the growth plate of developing bovine ribs. Biochem J 361: 231–241.
30.
Tholpady, S.S., T.F. Freyman, D. Chachra, R.C. Ogle (2003) Application of cyclic tensional force delays cranial suture fusion and activates TGF-beta signaling in vitro. Submitted.
31.
Warren, S.M., L.J. Brunet, R.M. Harland, A.N. Economides, M.T. Longaker (2003) The BMP antagonist noggin regulates cranial suture fusion. Nature 422: 625–629.
32.
Wolpert, L. (1982) Pattern formation and change; in Bonner, J.T. (ed): Evolution and Development. New York, Springer Verlag, pp 169–188.
33.
Yu, K., D.M. Ornitz (2001) Uncoupling fibroblast growth factor receptor 2 ligand binding specificity leads to Apert syndrome-like phenotypes. Proc Natl Acad Sci USA 98: 3641–3643.
34.
Zhou, Y.X., X. Xu, L. Chen, C. Li, S.G. Brodie, C.X. Deng (2000) A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9: 2001–2008.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.